The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Adam, a very fair post............""".Why would anybody have faith in this?""".....................and that is why I asked Uncanny the question. There are many variable that help calculate whether a share is fairly priced.
Do VAL have enough funds avaiable to progress trials to a point where the data is compelling?? Or indeed the will to do so.??
Is there any inflection based news to come in the short term to impact on the M/Cap??
Indeed what plans do the BOD have to increase the IP, and appeal to investors to back them in further clinical trials??
Why at this level do the BOD not increase any holdings they have to have more skin in the game?? That in itself is a worthy inflection point/
Uncanny your answer to my post was...........
"""What £2.5mn mkt cap compared to £16.5mn and £18.5mn of our closest peers?
Seems pretty obvious to me?!"""
Well, I wish you all goodnight on that one, Uncanny the best comment I can make on that is to say nothing., ....even I can understand why the market has valued Scancell at where it has, if you ever read that BB there are many reasons why investors can be hopeful of a very good return, there are also a few very good reasons why it jut might continue to fall.
As Adam just posted....................
""science can be amazing and the business can still fail."""
I don"t know anyboy on that BB who doesn"t consider that, it is only by considering different points of view, and the content of RNSs that we can best decide on that. And lets be fair if we did rely on RNS content, have the RNSs released by VAL for some time now, fairly refleted their value??
Night guys, another week.
Isn’t it obvious? Honestly, some of you lot need help! People need to buy some shares for this for it to be worth anywhere near that. They won’t because there is a very high chance that the lights will go out within months of them doing so. Also, the BOD are the least trustworthy on the entire market. Why would anybody have faith in this? The science can be amazing and the business can still fail.
What £2.5mn mkt cap compared to £16.5mn and £18.5mn of our closest peers? Seems pretty obvious to me?!
Uncanny - we all know that math is your strong point, and you have just proved it once again.
If you can't add up, then don't or ask for some help.
Roses your rollox is also laughable so the 1 for 25 and 1 for 125 would mean the share price today would be 11p which is completely irrelevant now. Why back track, why not stick to NOW. £2.5mn mkt cap and 894mn shares in issue. Our two closest peers are £16.5 and £18.7mn which is equivalent to 1.9 and 2.1p per share which makes VAL on better progressed IP 7 and 8 times undervalued.
Wow guess if you were subject to both consolidations your shares must be worth as close to £0 as to make no odds.
On that basis if you divide the sp by 125 and then by 25 you get 0.000096p. Uncanny you need to do some research, not soapbox rhetoric. So very glad I didn't pile in on your and others' exhortations over the last few months.
...Which would, I think, make each share worth .00263p. No wonder some folk are sitting on unrecoverable losses. But maybe not if your name begins with 'G' or 'S.'
Sorry, 1 for 25. And 1 for 125
But the calculation is still right
I can’t be bothered working it out at the moment but I’m sure someone will.
We have had two consolidations so far, the first was 25 shares for one and then next was 125 new shares foe each old one.
So to work out how many shares we really have in circulation without the share number hocus pocus just multiply our current shares in issue by 25 and then multiply that by 125
Sorry, that should read ‘. Over 100 BILLION shares in issue at the moment’
Uncanny - yet again you have shown complete lack of understanding of share consolidations and their effect on shares in issue.
Valirx have consolidated twice now and at this rate will be doing it again quite soon.
They were forced to consolidate as the shareprice fell below 0.1p and as it was below the nominal value of the shares, they were legally restricted from doing any more placings (it was either consolidate or go bankrupt )
If val had not consolidated then there would be over 10 billion shares in issue at the moment.
Seriously if you don’t understand something then don’t comment on it or ask for help.
Well done Drac, just shows you the difference in sentiment with SAR as compared to VAL at present. SAR More than 3 times as many shares in issue to VAL, VAL have a P2 compound finished and moving in to P3, SAR are twice our SP???? VAL are more advanced, less shares in issue but 1/8 of the valuation. Must be a massive rerate soon and maybe the catalyst is the next RNS’s on the updates. Also as 71mn shares issues to ABO, we’re not sure about the selling last week as the majority at .37 was buying, .35 sells of course but ABO are not dumping which to me suggests they are hanging around for newsflow. AIMHO and GLA all genuine shareholders.
I had It all In line.